Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
Leukemia
.
2015 Dec;29(12):2449-51.
doi: 10.1038/leu.2015.220.
Epub 2015 Sep 15.
Authors
A G Dinmohamed
1
,
Y van Norden
2
,
O Visser
3
,
E F M Posthuma
4
,
P C Huijgens
3
5
,
P Sonneveld
1
,
A A van de Loosdrecht
5
,
M Jongen-Lavrencic
1
Affiliations
1
Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
2
Clinical Trial Center-HOVON Data Center, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
3
Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
4
Department of Internal Medicine, Reinier de Graaf Group, Delft, The Netherlands.
5
Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
PMID:
26369829
DOI:
10.1038/leu.2015.220
No abstract available
Publication types
Letter
Comment
MeSH terms
Antimetabolites, Antineoplastic / therapeutic use*
Azacitidine / therapeutic use*
Female
Humans
Male
Myelodysplastic Syndromes / drug therapy*
Substances
Antimetabolites, Antineoplastic
Azacitidine